Valuation check: PFE's P/E ratio is 36.95, above the Healthcare sector average of 25.9.
Get informed when a big investor buys or sells
+ Follow36.95
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Pfizer (PFE) currently reports a P/E ratio of 36.95. That is above the Healthcare sector average of 25.9. Use the charts on this page to explore Pfizer's P/E ratio history and peer comparisons.
Pfizer's P/E ratio of 36.95 is higher than the Healthcare sector average of 25.9. That is roughly 42.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Pfizer's market price to a fundamental measure such as earnings, sales, or book value. At 36.95, PFE can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 36.95, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.9. From there, open related valuation or income-statement pages for Pfizer, and consider following PFE for alerts when major investors trade the stock.
Pfizer is classified in the Healthcare sector. On P/E ratio, it currently shows 36.95 versus a sector average near 25.9. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PFE with unrelated industries.